Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tubulis
Biotech
Gilead advances ADC dreams with potential $465M deal
Gilead is paying Munich-based biotech Tubulis $20M upfront, with the chance of a $30M option and up to $415M in milestone payments.
Darren Incorvaia
Dec 3, 2024 10:54am
Introducing Fierce Biotech's 2024 Fierce 15
Aug 5, 2024 6:00am
Tubulis rides wave of ADC interest to $138M financing round
Mar 14, 2024 9:12am
Bristol Myers pays Tubulis $23M to develop solid tumor ADCs
Apr 20, 2023 5:00am
Tubulis lands $63M to advance ADC pipeline led by Adcetris rival
May 3, 2022 5:00am
Tubulis raises A round to advance next-gen ADC programs
Jul 21, 2020 7:25am
